Everfront Biotech Inc.-EN

The Phase I Clinical Trial Results for Intracranial Implant - Cerebraca® Wafer (an investigational New Drug by Everfront Biotech Inc.) in Recurrent High-Grade Brain Cancer, by Prof. Shinn-Zong Lin in ACNS

Summary

  • Cerebraca® Wafer, an investigational new drug developed by Everfront Biotech Inc, has shown excellent safety and efficacy in its Phase I clinical trial for the treatment of recurrent malignant brain tumors.
  • The trial involved 12 patients, and those who received the highest dose had an average survival time of more than 19 months.
  • Cerebraca® Wafer is designed to clear residual malignant brain tumor cells after surgery and reduce chemoresistance with the help of TMZ.
  • The current standard treatments for recurrent malignant brain tumors have limited effectiveness, and there is an urgent need for new therapies.
Latest News
投資人青睞獎3

2023/5/5

Everfront Biotech Inc. Receives “Investor’s Choice Award” at the 2023 NBRP Demo Day Investment Matchmaking Competition

20221206

2022/12/6

Our Team Is Honored with the National Innovation Award – Clinical Innovation for Treating Recurrent Malignant Brain Tumors

20220609

2022/6/9

 Everfront Biotech’s Investigational product, Cerebraca® Wafer, has achieved significant progress in Phase I clinical trials for the treatment of malignant brain tumors, and has been invited to speak at the Asian Congress of Neurological Surgeons (ACNS).

1654158174614

2022/4/29

Everfront Biotech’s Cerebraca® Wafer has Completed the Phase I – Safety Evaluation for the Treatment of Glioblastoma Multiforme, and has Initiated the Phase IIa – Efficacy Evaluation

Development Pipeline